Consistent with the in vitro data, immunohistochemistry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses (Fig. 6D) of the xenograft tumors revealed that the ibrutinib/cisplatin combination effectively inhibited the tumor proliferation marker Ki-67. Here, MKI67 is linked to neoplasm.